Hypoxia-induced fibroblast growth factor 11 stimulates capillary-like endothelial tube formation

Yang,Jimin; Kim,Woo  Jean; Jun,Hyoung  Oh; Lee,Eun  Ju; Lee,Kyeong  Won; Jeong,Jae-Yeon; Lee,Sae-Won

doi:10.3892/or.2015.4223

Hypoxia-induced fibroblast growth factor 11 stimulates capillary-like endothelial tube formation

Authors:
- Jimin Yang
- Woo Jean Kim
- Hyoung Oh Jun
- Eun Ju Lee
- Kyeong Won Lee
- Jae-Yeon Jeong
- Sae-Won Lee
View Affiliations

Affiliations: Biomedical Research Institute and IRICT, Seoul National University Hospital, Seoul, Republic of Korea, National Research Laboratory of Regenerative Sexual Medicine, Department of Urology, Inha University School of Medicine, Incheon, Republic of Korea, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea, Marine Biotechnology Research Group, Korea Institute of Ocean Science and Technology, Ansan, Republic of Korea
Published online on: August 24, 2015 https://doi.org/10.3892/or.2015.4223
Pages: 2745-2751

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Low oxygen or hypoxia can be observed in the central region of solid tumors. Hypoxia is a strong stimulus for new blood vessel formation or angiogenesis, which is essential for tumor growth and progression. Fibroblast growth factor 11 (FGF11) is an intracellular non-secretory FGF whose function has not yet been fully characterized. In the present study, we demonstrated that FGF11 expression is upregulated under hypoxic conditions in human umbilical vein endothelial cells (HUVECs). FGF11 overexpression stimulated capillary-like tube formation, yet did not affect cell migration. Notably, FGF11 markedly increased the levels of tight junction proteins including occludin, zonula occludens-1 (ZO-1) and claudin-5 in HUVECs. The FGF11 promoter contains hypoxia response elements (HREs), and hypoxia-inducible factor-1 (HIF-1) binds to HREs to activate hypoxia-related genes. We demonstrated that hypoxia or HIF-1 expression under normoxic conditions increased the luciferase activity driven by the FGF11 promoter. However, deletion of the HREs from the FGF11 promoter rendered reporter gene activity unresponsive to hypoxia or HIF-1. Taken together, we propose that FGF11 may be involved in the stabilization of capillary-like tube structures associated with angiogenesis and may act as a modulator of hypoxia-induced pathological processes such as tumorigenesis.

View Figures

View References

1	Semenza GL: Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 15:551–578. 1999. View Article : Google Scholar
2	Lee SW, Jeong HK, Lee JY, Yang J, Lee EJ, Kim SY, Youn SW, Lee J, Kim WJ, Kim KW, et al: Hypoxic priming of mESCs accelerates vascular-lineage differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF. EMBO Mol Med. 4:924–938. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lee SW, Yang J, Kim SY, Jeong HK, Lee J, Kim WJ, Lee EJ and Kim HS: MicroRNA-26a induced by hypoxia targets HDAC6 in myogenic differentiation of embryonic stem cells. Nucleic Acids Res. 43:2057–2073. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lee SW, Lee YM, Bae SK, Murakami S, Yun Y and Kim KW: Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun. 268:456–461. 2000. View Article : Google Scholar : PubMed/NCBI
5	Lee SW, Won JY, Kim WJ, Lee J, Kim KH, Youn SW, Kim JY, Lee EJ, Kim YJ, Kim KW, et al: Snail as a potential target molecule in cardiac fibrosis: Paracrine action of endothelial cells on fibroblasts through snail and CTGF axis. Mol Ther. 21:1767–1777. 2013. View Article : Google Scholar : PubMed/NCBI
6	Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:485–490. 1998. View Article : Google Scholar : PubMed/NCBI
7	Moulder JE and Rockwell S: Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 10:695–712. 1984. View Article : Google Scholar : PubMed/NCBI
8	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
9	Holash J, Wiegand SJ and Yancopoulos GD: New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 18:5356–5362. 1999. View Article : Google Scholar : PubMed/NCBI
10	Dimmeler S and Zeiher AM: Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res. 87:434–439. 2000. View Article : Google Scholar : PubMed/NCBI
11	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
12	Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
13	Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9–22. 1999.PubMed/NCBI
14	Friesel RE and Maciag T: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J. 9:919–925. 1995.PubMed/NCBI
15	Yotsumoto F, Tokunaga E, Oki E, Maehara Y, Yamada H, Nakajima K, Nam SO, Miyata K, Koyanagi M, Doi K, et al: Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. Mol Cancer Res. 11:506–517. 2013. View Article : Google Scholar : PubMed/NCBI
16	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
17	Itoh N and Ornitz DM: Functional evolutionary history of the mouse Fgf gene family. Dev Dyn. 237:18–27. 2008. View Article : Google Scholar
18	Itoh N and Ornitz DM: Fibroblast growth factors: From molecular evolution to roles in development, metabolism and disease. J Biochem. 149:121–130. 2011. View Article : Google Scholar :
19	Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ and Kim KW: SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med. 9:900–906. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lee SW, Jung KH, Jeong CH, Seo JH, Yoon DK, Suh JK, Kim KW and Kim WJ: Inhibition of endothelial cell migration through the down-regulation of MMP-9 by A-kinase anchoring protein 12. Mol Med Rep. 4:145–149. 2011.PubMed/NCBI
21	Runkle EA and Mu D: Tight junction proteins: From barrier to tumorigenesis. Cancer Lett. 337:41–48. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ding I, Liu W, Sun J, Fenton B and Okunieff P: Comparison and modulation of angiogenic responses by FGFs, VEGF and SCF in murine and human fibrosarcomas. Comp Biochem Physiol A Mol Integr Physiol. 132:17–25. 2002. View Article : Google Scholar : PubMed/NCBI
23	Hu S, Li L, Yeh S, Cui Y, Li X, Chang HC, Jin J and Chang C: Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling. Mol Oncol. 9:44–57. 2015. View Article : Google Scholar
24	Zhuang Z, Jian P, Longjiang L, Bo H and Wenlin X: Oral cancer cells with different potential of lymphatic metastasis displayed distinct biologic behaviors and gene expression profiles. J Oral Pathol Med. 39:168–175. 2010. View Article : Google Scholar
25	Lee SW, Kim WJ, Jun HO, Choi YK and Kim KW: Angiopoietin-1 reduces vascular endothelial growth factor-induced brain endothelial permeability via upregulation of ZO-2. Int J Mol Med. 23:279–284. 2009.PubMed/NCBI
26	Brennan K, Offiah G, McSherry EA and Hopkins AM: Tight junctions: A barrier to the initiation and progression of breast cancer? J Biomed Biotechnol. 2010:4606072010. View Article : Google Scholar
27	Bouchagier KA, Assimakopoulos SF, Karavias DD, Maroulis I, Tzelepi V, Kalofonos H, Karavias DD, Kardamakis D, Scopa CD and Tsamandas AC: Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. In Vivo. 28:315–326. 2014.PubMed/NCBI
28	Nissi R, Talvensaari-Mattila A, Kuvaja P, Pääkkö P, Soini Y and Santala M: Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors. Anticancer Res. 35:973–976. 2015.PubMed/NCBI
29	Soini Y, Eskelinen M, Juvonen P, Kärjä V, Haapasaari KM, Saarela A and Karihtala P: Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma. Tumour Biol. 35:3803–3808. 2014. View Article : Google Scholar : PubMed/NCBI
30	Sugimoto H, Nagahara M, Bae Y, Nakagawa T, Ishikawa T, Sato T, Uetake H, Eishi Y and Sugihara K: Clinicopathologic relevance of claudin 5 expression in breast cancer. Am J Clin Pathol. 143:540–546. 2015. View Article : Google Scholar : PubMed/NCBI
31	Kleeff J, Shi X, Bode HP, Hoover K, Shrikhande S, Bryant PJ, Korc M, Büchler MW and Friess H: Altered expression and localization of the tight junction protein ZO-1 in primary and metastatic pancreatic cancer. Pancreas. 23:259–265. 2001. View Article : Google Scholar : PubMed/NCBI
32	Yang Y, Sun M, Wang L and Jiao B: HIFs, angiogenesis, and cancer. J Cell Biochem. 114:967–974. 2013. View Article : Google Scholar